Taiwan Cancer Moonshot Project: 1. Next-generation Pathway of Taiwan Cancer Precision Medicine (Subjective Aim 1- Taiwan Cancer Moonshot Project); 2. Development of Novel Treatments for Major Diseases (Subproject 5 - Multiomic Big Data-based Intelligent Navigation System for Precision Oncology)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Malignant Neoplasm of Body of Stomach in Situ
- Sponsor
- Academia Sinica, Taiwan
- Enrollment
- 4190
- Locations
- 1
- Primary Endpoint
- Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform.
Detailed Description
Multiomic integrative analysis is an effective strategy to facilitate the investigation of molecular mechanism, cause, and early intervention of specific diseases. Gastric cancer is specifically chosen for our research target to decrease its incidence and improve survival. To increase precision diagnosis, prognosis and precision therapy, patients from Taiwan are selected as cohort subjects. The aim of this study is to establish multiomic big data under strictly collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data then analyze by using integrated proteomics and genetics platform. Genome, transcriptome, genomic methylation, proteomics, and post-translational modification will be used to construct a map for determine the in-depth carcinogenesis of gastric cancer and strategies for cancer early diagnosis, prevention, and targeted treatments.
Investigators
Eligibility Criteria
Inclusion Criteria
- •lung cancer, breast cancer, gastric cancer, pancreatic cancer, ovarian cancer
Exclusion Criteria
- •other cancer types
Outcomes
Primary Outcomes
Collected clinical samples from tumors, adjacent normal tissue, blood, and clinical data
Time Frame: Through study completion, an average of 2 to 3 year
Analyze collected clinical samples by using integrated proteomics and genetics platform (genome, transcriptome, genomic methylation, proteomics, and post-translational modification)
Secondary Outcomes
- Differential expressed genes and proteins in tumor(Through study completion, an average of 4 year)